Comparison of Pregabalin and Ketotifen in treatment of uremic pruritus in hemodialysis patients
© 2022 Wiley Periodicals LLC..
This study aims to compare the efficiency of Pregabalin and Ketotifen in treatment of uremic pruritus in hemodialysis (HD) patients. Thirty HD patients were randomly divided into two groups: A (Pregabalin 50 mg three times a day) and B (Ketotifen 1 mg twice a day). Efficacy of treatment and quality of life were weekly evaluated by visual analogue scale (VAS) and Itchy Quality of life, respectively. There was no significant difference between the two groups regarding demographic features, laboratory data, quality of life, and VAS before treatment. In the second week of treatment, the pruritus intensity was significantly lower in the Pregabalin group than the Ketotifen group (p = 0.026). The mean of life quality was significantly lower in Ketotifen than Pregabalin group in weeks 1, 2, and 4 (p = 0.001, p = 0.001, and p = 0.036, respectively). There was no significant difference between the two groups regarding the side effects of drugs. This study showed that a higher dose of Pregabalin could be a more effective treatment than Ketotifen without additive side effects in improving the quality of life in dialysis patients.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:35 |
|---|---|
| Enthalten in: |
Dermatologic therapy - 35(2022), 7 vom: 09. Juli, Seite e15579 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Shamspour, Najmeh [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
55JG375S6M |
|---|
| Anmerkungen: |
Date Completed 14.07.2022 Date Revised 05.12.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1111/dth.15579 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM340811226 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM340811226 | ||
| 003 | DE-627 | ||
| 005 | 20231226010320.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/dth.15579 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1135.xml |
| 035 | |a (DE-627)NLM340811226 | ||
| 035 | |a (NLM)35557479 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Shamspour, Najmeh |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Comparison of Pregabalin and Ketotifen in treatment of uremic pruritus in hemodialysis patients |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 14.07.2022 | ||
| 500 | |a Date Revised 05.12.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2022 Wiley Periodicals LLC. | ||
| 520 | |a This study aims to compare the efficiency of Pregabalin and Ketotifen in treatment of uremic pruritus in hemodialysis (HD) patients. Thirty HD patients were randomly divided into two groups: A (Pregabalin 50 mg three times a day) and B (Ketotifen 1 mg twice a day). Efficacy of treatment and quality of life were weekly evaluated by visual analogue scale (VAS) and Itchy Quality of life, respectively. There was no significant difference between the two groups regarding demographic features, laboratory data, quality of life, and VAS before treatment. In the second week of treatment, the pruritus intensity was significantly lower in the Pregabalin group than the Ketotifen group (p = 0.026). The mean of life quality was significantly lower in Ketotifen than Pregabalin group in weeks 1, 2, and 4 (p = 0.001, p = 0.001, and p = 0.036, respectively). There was no significant difference between the two groups regarding the side effects of drugs. This study showed that a higher dose of Pregabalin could be a more effective treatment than Ketotifen without additive side effects in improving the quality of life in dialysis patients | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Randomized Controlled Trial | |
| 650 | 4 | |a Ketotifen | |
| 650 | 4 | |a Pregabalin | |
| 650 | 4 | |a uremic pruritus | |
| 650 | 7 | |a Pregabalin |2 NLM | |
| 650 | 7 | |a 55JG375S6M |2 NLM | |
| 650 | 7 | |a Ketotifen |2 NLM | |
| 650 | 7 | |a X49220T18G |2 NLM | |
| 700 | 1 | |a Aflatoonian, Mahin |e verfasserin |4 aut | |
| 700 | 1 | |a Khalili, Maryam |e verfasserin |4 aut | |
| 700 | 1 | |a Seifi, Mohsen |e verfasserin |4 aut | |
| 700 | 1 | |a Mousavi, Maryam |e verfasserin |4 aut | |
| 700 | 1 | |a Azmandian, Jalal |e verfasserin |4 aut | |
| 700 | 1 | |a Mohammadi, Saman |e verfasserin |4 aut | |
| 700 | 1 | |a Khoundabi, Batoul |e verfasserin |4 aut | |
| 700 | 1 | |a Parsimood, Elahenaz |e verfasserin |4 aut | |
| 700 | 1 | |a Mohebbi, Azadeh |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Dermatologic therapy |d 1998 |g 35(2022), 7 vom: 09. Juli, Seite e15579 |w (DE-627)NLM096394870 |x 1529-8019 |7 nnns |
| 773 | 1 | 8 | |g volume:35 |g year:2022 |g number:7 |g day:09 |g month:07 |g pages:e15579 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/dth.15579 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 35 |j 2022 |e 7 |b 09 |c 07 |h e15579 | ||